Terms: = Prostate cancer AND ATM, TELO1, 472, ENSG00000149311, TEL1, ATD, ATE, DKFZp781A0353, AT1, Q13315, MGC74674, ATDC, ATC, ATA AND Treatment
263 results:
1. Microwave hyperthermia enhances radiosensitization by decreasing DNA repair efficiency and inducing oxidative stress in PC3 prostatic adenocarcinoma cells.
Wu Y; Liu P; Chen W; Bai S; Chen S; Chen J; Xu X; Xia J; Wu Y; Lai J; Sun C; Lao Z; Wan X; Wu Z
Int J Hyperthermia; 2024; 41(1):2335201. PubMed ID: 38583875
[TBL] [Abstract] [Full Text] [Related]
2. Ductal, intraductal, and cribriform carcinoma of the prostate: Molecular characteristics and clinical management.
Shi Y; Wang H; Golijanin B; Amin A; Lee J; Sikov M; Hyams E; Pareek G; Carneiro BA; Mega AE; Lagos GG; Wang L; Wang Z; Cheng L
Urol Oncol; 2024 May; 42(5):144-154. PubMed ID: 38485644
[TBL] [Abstract] [Full Text] [Related]
3. Identification of Genes with Rare Loss of Function Variants Associated with Aggressive prostate cancer and Survival.
Saunders EJ; Dadaev T; Brook MN; Wakerell S; Govindasami K; Rageevakumar R; Hussain N; Osborne A; Keating D; Lophatananon A; Muir KR; ; Darst BF; Conti DV; Haiman CA; Antoniou AC; Eeles RA; Kote-Jarai Z
Eur Urol Oncol; 2024 Apr; 7(2):248-257. PubMed ID: 38458890
[TBL] [Abstract] [Full Text] [Related]
4. LCP1-mediated cytoskeleton alterations involve in arsenite-triggered malignant phenotype of human immortalized prostate stromal cells.
Yang Y; Zhou M; Huang Y; Ye X; Mo Y; Huang Y; Wang S
Food Chem Toxicol; 2024 Apr; 186():114548. PubMed ID: 38417537
[TBL] [Abstract] [Full Text] [Related]
5. Combined Cabazitaxel and Carboplatin Treatment of Metastatic Castration Resistant prostate cancer Patients, With Innate or Acquired Resistance to Cabazitaxel Monotherapy.
van der Zande K; Tutuhatunewa-Louhanepessy RD; Hamberg P; Ras S; de Feijter JM; Dezentjé VO; Broeks A; Cornelissen S; Beeker A; van der Noort V; Zwart W; Bergman AM
Clin Genitourin Cancer; 2024 Apr; 22(2):445-453.e1. PubMed ID: 38246830
[TBL] [Abstract] [Full Text] [Related]
6. DNA Damage Response and Mismatch Repair Gene Defects in Advanced and Metastatic prostate cancer.
Akhoundova D; Francica P; Rottenberg S; Rubin MA
Adv Anat Pathol; 2024 Mar; 31(2):61-69. PubMed ID: 38008971
[TBL] [Abstract] [Full Text] [Related]
7. Comprehensive genomic profiling testing in Japanese castration-resistant prostate cancer patients: results of a single-center retrospective cohort study.
Fukushima T; Goto K; Hayashi T; Ikeda K; Hatayama T; Yamanaka R; Iwane K; Tasaka R; Kohada Y; Takemoto K; Kobatake K; Goriki A; Toshida A; Nakahara H; Motonaga M; Tokumo K; Fujii Y; Hayes CN; Okamoto W; Kubo T; Matsumoto T; Shiota M; Yamamoto N; Urabe Y; Hiyama E; Arihiro K; Hinoi T; Hinata N
Jpn J Clin Oncol; 2024 Feb; 54(2):175-181. PubMed ID: 37899139
[TBL] [Abstract] [Full Text] [Related]
8. atm-AMPKα mediated LAG-3 expression suppresses T cell function in prostate cancer.
Zhang X; Chen H; Han J; Wang Z; Guo Y; Zhou Z; Luo R; Dai M; Ou W; Chen L; Shao L
Cell Immunol; 2023; 393-394():104773. PubMed ID: 37857190
[TBL] [Abstract] [Full Text] [Related]
9. Diagnostic capability of 18F-PSMA PET-MRI and pelvic MRI plus bone scan in treatment-naive prostate cancer: a single-center paired validating confirmatory study.
Qiao Z; Wang S; Wang H; He B; Shi Z; Zhou H; Yang Q; Chen X; You Z; Zhao J; Wang H
Int J Surg; 2024 Jan; 110(1):87-94. PubMed ID: 37738021
[TBL] [Abstract] [Full Text] [Related]
10. A Crosstalk Between Castration-Resistant prostate cancer Cells, M2 Macrophages, and NK Cells: Role of the atm-PI3K/AKT-PD-L1 Pathway.
Jin H; Zhu J; Xuan R; Zhou Y; Xue B; Yang D; Gao J; Zang Y; Xu L
Immunol Invest; 2023 Nov; 52(8):941-965. PubMed ID: 37732622
[TBL] [Abstract] [Full Text] [Related]
11. Efficacy and safety of PARP inhibitors in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis of clinical trials.
Iannantuono GM; Chandran E; Floudas CS; Choo-Wosoba H; Butera G; Roselli M; Gulley JL; Karzai F
Cancer Treat Rev; 2023 Nov; 120():102623. PubMed ID: 37716332
[TBL] [Abstract] [Full Text] [Related]
12. Mechanistic study of dual-function inhibitors targeting topoisomerase II and Rad51-mediated DNA repair pathway against castration-resistant prostate cancer.
Chiang YC; Leu WJ; Chen YC; Ye PC; Hsu YT; Hsiao YC; Hsu JL; Chan SH; Hsu LC; Huang HS; Guh JH
Prostate; 2023 Dec; 83(16):1549-1563. PubMed ID: 37583103
[TBL] [Abstract] [Full Text] [Related]
13. BRCA-deficient metastatic prostate cancer has an adverse prognosis and distinct genomic phenotype.
Fettke H; Dai C; Kwan EM; Zheng T; Du P; Ng N; Bukczynska P; Docanto M; Kostos L; Foroughi S; Brown S; Graham LK; Mahon K; Horvath LG; Jia S; Kohli M; Azad AA
EBioMedicine; 2023 Sep; 95():104738. PubMed ID: 37549632
[TBL] [Abstract] [Full Text] [Related]
14. Investigation of Clinically Significant Molecular Aberrations in Patients with prostate cancer: Implications for Personalized Treatment, Prognosis and Genetic Testing.
Fountzilas E; Kouspou M; Eliades A; Papadopoulou K; Bournakis E; Goussia A; Tsiatas M; Achilleos A; Tsangaras K; Billioud G; Loizides C; Lemesios C; Kypri E; Ioannides M; Koumbaris G; Levva S; Vakalopoulos I; Paliouras A; Pervana S; Koinis F; Bumci R; Christopoulou A; Meditskou S; Psyrri A; Boukovinas I; Visvikis A; Karavasilis V; Koukoulis GK; Kotsakis A; Giannakis D; Fountzilas G; Patsalis PC
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511593
[TBL] [Abstract] [Full Text] [Related]
15. prostate cancer: Under-representation of African American Men in Research Studies Used in the Latest NCCN Guidelines.
Lubarsky R; Ambinder D; Barnett J; Choudhury M; Saji A; Fishman AI; Fullerton S; Phillips JL
Urology; 2023 Oct; 180():28-34. PubMed ID: 37479145
[TBL] [Abstract] [Full Text] [Related]
16. Rutin is a potent senomorphic agent to target senescent cells and can improve chemotherapeutic efficacy.
Liu H; Xu Q; Wufuer H; Li Z; Sun R; Jiang Z; Dou X; Fu Q; Campisi J; Sun Y
Aging Cell; 2024 Jan; 23(1):e13921. PubMed ID: 37475161
[TBL] [Abstract] [Full Text] [Related]
17. Uncommon variants detected via hereditary cancer panel and suggestions for genetic counseling.
Özdemir Z; Çevik E; Öksüzoğlu ÖBÇ; Doğan M; Ateş Ö; Esin E; Bilgetekin İ; Demirci U; Köseoğlu Ç; Topal A; Karadurmuş N; Erdem HB; Bahsi T
Mutat Res; 2023; 827():111831. PubMed ID: 37453313
[TBL] [Abstract] [Full Text] [Related]
18. Genetic landscape of homologous recombination repair genes in early-onset/familial prostate cancer patients.
Paulo P; Cardoso M; Brandão A; Pinto P; Falconi A; Pinheiro M; Cerveira N; Silva R; Santos C; Pinto C; Peixoto A; Maia S; Teixeira MR
Genes Chromosomes Cancer; 2023 Dec; 62(12):710-720. PubMed ID: 37436117
[TBL] [Abstract] [Full Text] [Related]
19. Veratramine Inhibits the Cell Cycle Progression, Migration, and Invasion via atm/ATR Pathway in Androgen-Independent prostate cancer.
Kim HY; Lee SW; Choi SK; Ashim J; Kim W; Beak SM; Park JK; Han JE; Cho GJ; Ryoo ZY; Jeong J; Lee YH; Jeong H; Yu W; Park S
Am J Chin Med; 2023; 51(5):1309-1333. PubMed ID: 37385965
[TBL] [Abstract] [Full Text] [Related]
20. Rucaparib for the Treatment of Metastatic Castration-resistant prostate cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study.
Abida W; Campbell D; Patnaik A; Bryce AH; Shapiro J; Bambury RM; Zhang J; Burke JM; Castellano D; Font A; Ganju V; Hardy-Bessard AC; McDermott R; Sautois B; Spaeth D; Voog E; Piulats JM; Pintus E; Ryan CJ; Merseburger AS; Daugaard G; Heidenreich A; Fizazi K; Loehr A; Despain D; Simmons AD; Dowson M; Go J; Watkins SP; Chowdhury S
Eur Urol; 2023 Sep; 84(3):321-330. PubMed ID: 37277275
[TBL] [Abstract] [Full Text] [Related]
[Next]